Ciki na Ciki akan Kudin Maganin Ciwon Kankara a Indiya - Wahayi Dole-Karanta!
Ciwon daji na nono yana da kashi 31% na dukkan cututtukan da aka gano a cikin matan Indiya, wanda ya sa ya zama farkon nau'in ciwon daji. Dole ne a kula da wannan mummunar cuta a farkon mataki don sakamako mafi kyau. Shafin namu ya karyata ciwon nono t..
Abemaciclib, mai hana aromatase, Eli Lilly da kamfanin, endocrine far, Tamoxifen, Verzenio
Abemaciclib tare da maganin endocrin an yarda da FDA a cikin HER 2 tabbataccen ciwon nono
Maris 2023: Abemaciclib (Verzenio, Eli Lilly da Kamfani) da kuma maganin endocrine (tamoxifen ko mai hana aromatase) Hukumar Abinci da Magunguna (FDA) ta amince da ita don kula da tsofaffi marasa lafiya tare da ..
Sin, Enhertu, TA 2 tabbatacce
An amince da Enhertu a China don majinyata da ke da HER2-tabbataccen ciwon nono
Feb 2023: Enhertu (trastuzumab deruxtecan) from AstraZeneca and Daiichi Sankyo has been approved as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received ..
Hamsa, Hamsa Nandini, Mirchi, fim din Mirchi
Jarumi Hamsa Nandini Ya Bada Sabunta Shekara Daya Bayan Maganin Ciwon Kansa Na Nono
Feb 2023: Hamsa Nandini, wacce aka gano tana dauke da Carcinoma Grade III Invasive Carcinoma (Cusar Nono) a cikin 2021, ta sabunta mabiyanta na Instagram kan yanayin lafiyarta. Jarumar wadda ta fito a fina-finan Telugu kamar Mirchi da Lege.
Kimiyya ta Gilead, sacituzumab govitecan-hziy, Trodelvy, TROPiCS-02
FDA ta amince da Sacituzumab govitecan-hziy don ciwon nono mai HR mai kyau
Feb 2023: The Food and Drug Administration (FDA) has approved sacituzumab govitecan-hziy (Trodelvy, Gilead Sciences, Inc.) for people with hormone receptor (HR)-positive, HER2-negative (IHC 0, IHC 1+, or IHC 2+/ISH-) breast cance..
elacestrant, Orserdu, Stemline Therapeutics
Elacestrant an amince da shi ta FDA don ER-tabbatacce, HER2-negative, ESR1-mutated ci-gaba ko ciwon nono metastatic
In February 2023, the Food and Drug Administration (FDA) approved elacestrant (Orserdu, Stemline Therapeutics, Inc.) for women or men over 50 who have advanced or metastatic breast cancer and are ER-positive, HER2-negative, and h..
Daichi Sankyo, Enhertu, fam-trastuzumab deruxtecan-nxki
Fam-trastuzumab deruxtecan-nxki FDA ta amince da shi don ciwon nono
Afrilu 2022: Manya marasa lafiya tare da ciwon nono maras ganewa ko metastatic HER2-tabbataccen ciwon nono waɗanda suka karɓi tsarin tushen anti-HER2 na baya ko dai a cikin saitin metastatic, ko a cikin neoadjuvant ko saitin adjuvant kuma sun haɓaka.
AstraZeneca Pharmaceuticals, BRCA, gBRCAm, Lynparza, olaparib, OlympiA
An amince da Olaparib don maganin cutar kansa mai haɗari da wuri
Maris 2022: Hukumar Abinci da Magunguna ta amince da olaparib (Lynparza, AstraZeneca Pharmaceuticals, LP) don kula da tsofaffi marasa lafiya tare da lalata ko ake zargi da lalata germline BRCA-mutated (gBRCAm) h..
Abemaciclib, Wakil, Dako Omnis, Eli Lilly da kamfanin, endocrine far, Tamoxifen, Verzenio
Abemaciclib ya amince da FDA tare da maganin endocrin don ciwon nono na farko
Oktoba 2021: Hukumar Abinci da Magunguna ta amince da abemaciclib (Verzenio, Eli Lilly da Kamfani) a haɗe tare da maganin endocrin (tamoxifen ko mai hana aromatase) don kulawa da balagaggu na manya marasa lafiya tare da ho.
KEYTRUDA, Merck, Pembrolizumab, TNBC
FDA ta amince da Pembrolizumab don babban haɗarin farkon cutar kansa sau uku
Agusta 2021: FDA ta amince da Pembrolizumab (Keytruda, Merck) don babban haɗari, farkon cutar kansa mai cutar kansa sau uku (TNBC) a matsayin magani neoadjuvant a haɗe tare da ilimin jiyya, kuma daga baya a matsayin wakili ɗaya azaman adjuv ..